Cargando…

Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth

A goal of HIV vaccine development is to elicit antibodies with neutralizing breadth. Broadly neutralizing antibodies (bNAbs) to HIV often have unusual sequences with long heavy-chain complementarity-determining region loops, high somatic mutation rates and polyreactivity. A subset of HIV-infected in...

Descripción completa

Detalles Bibliográficos
Autores principales: Roskin, Krishna M., Jackson, Katherine J. L., Lee, Ji-Yeun, Hoh, Ramona A., Joshi, Shilpa A., Hwang, Kwan-Ki, Bonsignori, Mattia, Pedroza-Pacheco, Isabela, Liao, Hua-Xin, Moody, M. Anthony, Fire, Andrew Z., Borrow, Persephone, Haynes, Barton F., Boyd, Scott D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223457/
https://www.ncbi.nlm.nih.gov/pubmed/31959979
http://dx.doi.org/10.1038/s41590-019-0581-0
Descripción
Sumario:A goal of HIV vaccine development is to elicit antibodies with neutralizing breadth. Broadly neutralizing antibodies (bNAbs) to HIV often have unusual sequences with long heavy-chain complementarity-determining region loops, high somatic mutation rates and polyreactivity. A subset of HIV-infected individuals develops such antibodies, but it is unclear whether this reflects systematic differences in their antibody repertoires or is a consequence of rare stochastic events involving individual clones. We sequenced antibody heavy-chain repertoires in a large cohort of HIV-infected individuals with bNAb responses or no neutralization breadth and uninfected controls, identifying consistent features of bNAb repertoires, encompassing thousands of B cell clones per individual, with correlated T cell phenotypes. These repertoire features were not observed during chronic cytomegalovirus infection in an independent cohort. Our data indicate that the development of numerous B cell lineages with antibody features associated with autoreactivity may be a key aspect in the development of HIV neutralizing antibody breadth.